title: Experience with a cross-study endpoint review committee for AIDS clinical trials. Terry Beirn Community Programs for Clinical Research on AIDS.
abstract: OBJECTIVE
  To describe the methods and results of a standardized system for clinical endpoint determination for defining and reviewing endpoints in clinical trials for HIV-infected individuals.
  
  
  METHODS
  A system was developed utilizing standard definitions for the 24 diagnoses or clinical events that serve as trial endpoints and together define the combined endpoint 'progression of HIV disease. A common set of case report forms were used for all trials. Thus, an event of Pneumocystis carinii pneumonia (PCP), for example, for a subject co-enrolled in an antiretroviral trial and a PCP prophylaxis trial was only reported once.
  
  
  METHODS
  A central committee was established to define clinical events and review endpoints across all studies. Events were classified according to established criteria for confirmed, probable and possible levels of certainty.
  
  
  RESULTS
  This report describes the methods used to ascertain and review endpoints, and summarized 2299 clinical events for 8097 subjects enrolled in one or more of nine clinical trials. Data on the diagnostic certainty of events and agreement between site clinicians and the endpoint committee are presented.
  
  
  CONCLUSIONS
  Uniform classification of endpoints across AIDS clinical trials can be accomplished by multicenter, multitrial organizations with standardized definitions and review of endpoint documentation. Our experience suggests that nurse coordinators reviewing all submitted endpoints for every trial are warranted and the need for external review by a clinical events committee may depend on the type of trial conducted.
authors.affiliation: CPCRA Statistical Center, University of Minnesota, Minneapolis 55414, USA.
authors.forename: L A
authors.initials: LA
authors.lastname: Green
authors.forename: F S
authors.initials: FS
authors.lastname: Rhame
authors.forename: R W
authors.initials: RW
authors.lastname: Price
authors.forename: D C
authors.initials: DC
authors.lastname: Perlman
authors.forename: L G
authors.initials: LG
authors.lastname: Capps
authors.forename: J H
authors.initials: JH
authors.lastname: Sampson
authors.forename: L R
authors.initials: LR
authors.lastname: Deyton
authors.forename: S M
authors.initials: SM
authors.lastname: Schnittman
authors.forename: E J
authors.initials: EJ
authors.lastname: Fisher
authors.forename: G E
authors.initials: GE
authors.lastname: Bartsch
authors.forename: E A
authors.initials: EA
authors.lastname: Krum
authors.forename: J D
authors.initials: JD
authors.lastname: Neaton
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000145:classification; D002986:Clinical Trials as Topic / Q000592:standards*; D003625:Data Collection / Q000379:methods; D018450:Disease Progression; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D016896:Treatment Outcome